Surgery

Does surgery extend survival?


This 2014 study The efficacy of surgical treatment of cancer – 20 years later concluded:
No benefits can be expected to be achieved from using cancer surgery except in a few immediately life-threatening situations. Surgery appears to be based on an invalid paradigm of what cancer is. Cancer appears to be a systemic disease and therefore standard treatments need to be reassessed in this light…

It would therefore appear that the figure of about 60% five-year survival often quoted for cancer intervention in general, and claimed to have increased in recent years as a result of improved treatment, represents what survival would have been without intervention, i.e. the natural survival without treatment.

Diagnosis of cancer under a situation where the diagnosis is to be followed by surgery, particularly a diagnosis following cancer screening, can only result in over-treatment and lead to harm. This can only be avoided if a therapy is used based on a valid paradigm of what cancer is.

This study found:
No correlation was found between reduced breast cancer mortality and earlier surgical intervention. In fact, the trial with the most earlier surgical intervention had the smallest reduction in mortality; and that with the least earlier surgical intervention had the largest reduction in mortality.

This demonstrates that the earlier-diagnosis hypothesis is invalid. Some correlation was established between reduced mortality and reduced use of radiotherapy, suggesting that radiotherapy had a greater influence on mortality than surgery…The conclusion from the previous analysis, that surgery has not been shown to reduce mortality for any form of cancer, is therefore still valid.

Because of the ethical problems of providing a proper control group of untreated patients, no scientifically acceptable trials have ever been carried out to prove that surgery is ‘effective’ in extending life.

D.J. Benjamin

This study The efficacy of surgical treatment of cancer concluded:
In summary, surgery became an ‘accepted’ treatment for cancer as a result of several factors. Because of the ethical problems of providing a proper control group of untreated patients, no scientifically acceptable trials have ever been carried out to prove that surgery is ‘effective’ in extending life. A graphical method used for analysing mortality rates suggests that there is no difference in survival between treated and untreated patients.

Comparative studies of surgical techniques using differing degrees of excision show no difference in survival. This would be expected if tumours were only symptoms of a systemic disease. Percentage 5-year survival statistics offered to show that surgery is an increasingly effective method of cancer treatment are unreliable because of several methodological problems.

The difference between incidence and mortality, which is a more reliable measure of the effects of surgery on cancer control, suggests that no improvement in survival has occurred as a result of surgery. The best, properly documented results of survival with terminal cancer patients have been achieved using therapies based on the hypothesis that cancer is a systemic disease and therefore should be treated by methods designed to restore the body’s own natural immune system.

Surgery has therefore not been shown to be an effective or proven method for the treatment of cancer. These findings add weight to the hypothesis that cancer is a systemic disease when first diagnosed.


Having Breast surgery?

This study says: An intriguing controversy regarding the surgical treatment of breast cancer patients in the last two decades was initiated following a publication by Hrushesky et al. who reported that the timing of surgery for the resection of breast cancer tumors within the menstrual cycle influences disease recurrence and patient survival rates. Since then, several independent groups have corroborated these surprising findings, suggesting that the optimal time for the resection is the early luteal phase*. This phenomenon was independent of estrogen receptor status and more prominent in node-positive women.

[ *The luteal phase: The time between ovulation and before the start of menstruation]

What are the dangers of surgery?

Possible complications for any surgical procedure include:


Atrial fibrillation after surgery increases risk of heart attacks, strokes
An irregular heartbeat following surgery known as post-operative atrial fibrillation (POAF) often is dismissed as a transient phenomenon. But a study has found that POAF can significantly increase the risk of heart attack or stroke during the first 12 months after surgery.

Sources: Mayo ClinicScience Daily / University of TorontoNHSAmerican Cancer Society


Do Biopsies cause metastasis?


Biopsies can promote metastasis via neoplasm seeding.

Neoplasm Seeding
The unintentional release of cancer cells from a tumor by a biopsy needle or surgical instrument, which then spread to other parts of the body resulting in new tumor formation.

In this video cancer survivor /coach Chris Wark  (chrisbeatcancer.com) says: In 2004 at the John Wayne Cancer Center, they did a study on women with aggressive breast tumors. One group had needle biopsy and then surgery a few weeks later. The other group did not have the biopsy, they just had the surgery to remove the lump. The group that had the biopsy first had a 50% increase in malignancy, that means the cancer spreading after surgery.

So, just that tiny needle biopsy caused what they call “seeding,” which is where you poke a tumor; cancer cells spill out and they spread around in the surrounding tissues and that can cause the tumor to spread.

Because when they come to take the tumor out, they’re taking the tumor, but they’re not taking out the cells that spread after the biopsy.
 Now, the same thing can happen with a major surgery. Your body’s response to heal that surgery is actually like cancer fuel, because your body secretes all these growth hormones to heal itself after a major surgery and those growth hormones are cancer cell fuel.

So on one hand, surgery can be beneficial because you’re removing a tumor and getting a big bulk of cancer cells out of your body. But on the other hand, it can also cause the cancer to spread.

Watch the full video at chrisbeatcancer.com
See the study.


This published review says: Many a times to obtain sufficient amount of sample during needle biopsy for diagnosis the tumor may need to be penetrated several times. This repeated puncturing and manipulation inside the tumor mass with needle may seed tumor cells into the needle track and also may spill the cancerous cells directly in to the circulation.


Does Surgery cause metastasis?

Surgery can promote metastasis in a number of ways, including:

Promoting Angiogenesis (formation of new blood vessels)
Causing Inflammation
Damaging your Immune System

The following can also have an effect on surgery outcome:
Timing of Surgery
Invasiveness of Surgery
Choice of Surgical Anaesthesia
Choice of post-surgery Analgesic drugs (pain killers)

All these can be addressed using the products and strategies listed below (backed by studies which are published further down the page)

But first, here are some supporting studies:

This study says: Given that evidence is continuously accumulating to support the hypothesis that surgery is a facilitator of the metastatic process, it is critical to consider the alarming clinical notion that surgery is a double-edged sword—it is necessary and life-saving; yet, has deleterious long-term impacts, potentially increasing the risk of metastases. We believe that surgery is indeed a major risk factor for the spread, establishment, and growth of malignancy…We believe that the integration of etodolac and propranolol into the preoperative setting of oncological surgery will improve postoperative well-being and decrease long-term recurrence rates in patients with breast, colon, and other types of cancer.

[ Etodolac is a nonsteroidal anti-inflammatory drug (NSAID)
Propranolol is a type of medicine called a beta blocker.]

Here is a case study

Post-Traumatic IBC (Inflammatory breast carcinoma)

This 33 year old woman was in good health and was employed as a civilian working for the military in Guam when she decided to have her nipples pierced. The procedure was performed in early 1999 and subsequently she noticed that the right nipple slowly began to swell. By the end of December the swelling was very prominent and she had the ring removed. On 1 January 2000 she noted a large lump behind the areola. She was able to get an ultrasound in Guam and noticed that the lump had doubled in size in the next five days; she also developed pain with intermittent stinging sensations but no redness.

Her original Ob/Gyn doctor in Guam thought it to be an infection and put her on antibiotics. While traveling back to the U.S. where she was hired for a job in Washington, DC, the patient developed erythema of the entire breast with a thumb size port wine stain laterally. She noted that the lump was now of the size of a grapefruit.

On evaluation in the U.S. 28 January 2000 the right breast was noted to be tender, painful and swollen with hyperemia, dermal thickening and induration especially in the inferolateral breast. A mammogram that day showed only nonspecific changes suggestive of mastitis.

She was treated with antibiotics with no improvement. A biopsy of an indurated part of the port wine stain documented a malignancy and the diagnosis of IBC was made. The mass grew quickly involving more than half the breast with peau d’orange appearance and she received four cycles of Adriamycin and cytoxan with excellent response. Mastectomy performed in June 2000 showed infiltrating ductal carcinoma with involved margins and dermal/lymphovascular invasion. All five lymph nodes examined showed metastatic disease. In May 2001 she developed severe back pain and MRI suggested lesions in C7 and T11. She was started on radiation therapy but in June she developed lung lesions and she was treated with taxotere followed by herceptin and letrozole. Her disease persisted but she continued treatment and survived until June 2010.

Study: Metastasis is a common cause of morbidity and mortality in cancer patients. Both experimental and clinical evidence lend support to the idea that surgery which is intended to be a curative option to remove and reduce tumor mass, can paradoxically also augment development of metastases.

Study: We have shown indirect but compelling evidence that there is dormancy in breast cancer and that surgery to remove the primary tumor does occasionally break dormancy.

Study: Primary tumor removal, usually considered intrinsically beneficial, can perturb metastatic homeostasis, and for some patients results in the acceleration of metastatic cancer.

Study: The role of breast tumour removal is different from the role of surgery by itself. Our findings suggest that the major effect of reconstructive surgery is microscopic metastasis acceleration, while breast tumour surgical removal (either primary or IBTR or CBC) involves both tumour homeostasis interruption and microscopic metastasis growth acceleration.

This 2017 Study published by the American Association for Cancer Research says: Both experimental and clinical evidence lend support to the idea that surgery which is intended to be a curative option to remove and reduce tumor mass, can paradoxically also augment development of metastases.

An article published on the UKs number one cancer website canceractive.com includes the following important points:


How can I reduce risk of metastasis during surgery?

You can:

Inhibit angiogenesis (growth of new blood vessels)
EGCG (green tea) 
Curcumin

Genistein (food supplement)  
Silymarin (extract of milk thistle seeds)
Cannabis


Inhibit COX-2 (reduces inflammation)
Aspirin
Resveratrol
Genistein 
ECGC (Green Tea)
Curcumin  
Quercetin (a plant pigment)  
Fish oil  
Garlic Feverfew (plant extract)  
Silymarin (extract of milk thistle seeds)  
Sodium Butyrate (sodium salt of butyric acid)
 
Boost your Immunity (enhances NK cell activity)
PSK (medicinal mushroom extracts)
IP-6 ( a vitamin-like substance)
AHCC (fermented mushroom extract)  
Curcumin
Mistletoe
Aged Garlic Extract (AGE) 
Lactoferrin (protein found in milk)

Useful Strategies and their Proven Benefits

The Luteal Phase = The optimal time for breast cancer surgery

Laparoscopy = Less invasive surgery – may reduce metastasis

Video-assisted Thoracic Surgery (VATS) lobectomy = Less invasive surgery – may reduce metastasis

General or Locoregional anaesthesia? Locoregional anaesthesia may be better

Morphine, Tramadol, or CBD? Tramadol or CBD may be better option    

Here is scientific evidence supporting the efficacy of all the items listed above.

Angiogenesis

Angiogenesis is the formation of new blood vessels Angiogenesis plays a critical role in the growth of cancer because solid tumors need a blood supply if they are to grow beyond a few millimeters in size. Tumors can actually cause this blood supply to form by giving off chemical signals that stimulate angiogenesis. – National Cancer Institute.

This study says it is known that after surgery a sharp spike in angiogenesis stimulators and growth factors occurs to aid in wound healing. Thus, it is not surprising that tumour angiogenesis and proliferation result after surgery to remove a primary tumour. Therefore, a likely trigger for kick-starting the growth of micro-metastases, could be the act of surgery itself… It suggests that surgery could be responsible for accelerating the clinical appearance of metastatic disease.

The following can inhibit angiogenesis

EGCG (green tea)
This study says:  EGCG inhibits the growth of gastric cancer by reducing VEGF production and angiogenesis, and is a promising candidate for anti-angiogenic treatment of gastric cancer.
This study says: These findings support the hypothesis that EGCG, a major green tea catechin, directly targets both tumor cells and tumor vasculature, thereby inhibiting tumor growth, proliferation, migration, and angiogenesis of breast cancer,

Curcumin
This study says: In summary, our present study indicates that curcumin is a potent inhibitor of angiogenesis…Given the importance of angiogenesis and tumour neovascularisation in cancer progression, our data also suggest that the anticancer effects of curcumin may also involve direct effects on local microvascular populations.

This study says: According to our study, curcumin inhibits tumor growth, tumor angiogenesis and induces apoptosis of endothelial cells, and suppresses HIF-1 mediated VEGF production and VEGF mediated signaling pathways.

Genistein
This study says: These observations support the hypothesis that genistein may inhibit prostate tumor angiogenesis…

NOTE:  This study states: In this model, a bivalent effect of genistein was demonstrated on sprouting angiogenesis, with angiogenic stimulation at low concentrations (0.001–1 µM) and inhibition at higher ones (25–100 µM).

Silymarin (SM)
This study says:
This study was designed to evaluate the anti-angiogenic effect of silymarin (SM) and its major pure component silibinin (SB), and also thalidomide (TH). Conclusion. SM/SB has a strong anti-angiogenesis effect on the colon cancer cell line, and this might provide an alternative treatment option for anticancer treatment.

Five days prior to surgery, the patient may consider supplementing with standardized green tea extract, curcumin, soy genistein extract and other nutrients that suppress VEGF and thus may help protect against angiogenesis.

Cannabis
According to the National Cancer Institute  Cannabinoids, also known as phytocannabinoids, are chemicals in Cannabis that cause drug-like effects in the body, including the central nervous system and the immune system. Cannabinoids may cause antitumor effects by various mechanisms, including induction of cell death, inhibition of cell growth, and inhibition of tumor angiogenesis invasion and metastasis.

A study published in the Journal Molecular Cancer showed that THC reduced tumour growth and tumour numbers. They determined that cannabinoids inhibit cancer cell proliferation, induce cancer cell apoptosis and impair tumour angiogenesis .
See Cannabinoids page


Cancer Surgery and Inflammation

Cancer surgery increases the production of inflammatory chemicals, such as interleukin-1 and interleukin-6. These increase the activity of COX-2 – a highly potent inflammatory enzyme involved in promoting cancer growth and metastasis.

This study says: Elevated expression of COX-2 is a common characteristic of many human carcinomas. COX-2 plays an important role in tumorigenesis as mediating the progression and metastasis of tumors, such as nasopharyngeal carcinoma, hepatocellular carcinoma, lung cancer and melanoma. The differential expression of COX-2 highly correlates to the progression of malignant melanoma and severely impairs the survival of patients.

This study says: (COX-2)…is associated with inflammatory diseases and carcinogenesis, which is suspected to promote angiogenesis and tissue invasion of tumors and resistance to apoptosis. Meanwhile, COX-2 contributes to immune evasion and resistance to cancer immunotherapy….

COX-2 Inhibitors:

Aspirin (See also: Pycnogenol – Aspirin alternative at https://cancerireland.ie/aspirin/

Resveratrol
This study says: …the results of the present study clearly show that resveratrol suppressed the synthesis of PGE2 by inhibiting COX-2 enzyme activity.  https://cancerireland.ie/resveratrol-and-mske/

Genistein (Soy isoflavones)
This study says: We found in this study that genistein in combination with EPA and DHA [both are fatty acids ] affected the expression of COX-2…

Green tea (EGCG)
This study concluded: In conclusion, these data suggest that inhibition of COX-2 is a mechanism for the anti-proliferative effect of green tea and emphasizes the role that dietary factors have as anti-cancer agents… Green tea and its derived compounds such as EGCG offer several advantages as putative anticancer agents; the foremost being that they are non-toxic to normal cells, produce few side effects, and are widely available.

Curcumin
This study says: Curcumin markedly inhibited the mRNA and protein expression of COX-2, but not COX-1…Therefore, curcumin may be superior to commonly used NSAIDs, which have anti-inflammatory and chemopreventive effects. Moreover, our study demonstrates for the first time that curcumin does not alter the expression of COX-1, so additional benefits may be gained by this agent over NSAIDs. In conclusion, our study suggests that curcumin should be considered as a possible safe and nontoxic chemopreventive agent for colorectal cancer in humans.
https://cancerireland.ie/curcumin/

Quercetin
This study says: These results indicate that quercetin suppresses COX-2 expression by inhibiting the p300 signaling and blocking the binding of multiple transactivators to COX-2 promoter. Our findings therefore reveal a novel mechanism of action of quercetin and suggest a potential use for quercetin in the treatment of COX-2-mediated diseases such as breast cancers.

Fish oil
This study says: …fish oils contain the natural COX inhibitor EPA, which inhibits both COX-1 and COX-2 activity… In a medical environment in which messages molded by pharmaceutical interests stress the ‘need’ for NSAIDs, prescribers should consider the NSAID-sparing effects, the lack of serious side effects and the positive health benefits of fish oil. Importantly, recipients should be informed that there is a ‘mainstream’ evidence base for such a recommendation…

Garlic
This study says: In this study we report on the effectiveness of diallyl sulphides (DAS), which are derivatives of garlic, as potent COX-2 inhibitors.

This study says: Ajoene, a garlic-derived natural product that interfaces with the COX-2 enzyme, has anti-cancer activities

Feverfew
This study says: Feverfew appears to be an inhibitor of prostaglandin synthesis, leukotrienes (LT) and expression of pro-inflammatory cytokines…Further studies revealed that it inhibits inflammatory mediators including activity and expression of cyclo-oxygenase (COX) specifically COX-2, which also enhances cancer stem-like cells’ characteristics such as higher colony formation efficiency and over expression of stemness-associated genes

Silymarin (milk thistle)
This study says: Silymarin treatment significantly inhibited the expression of COX-2, thereby maintaining increased levels of free arachidonic acid in the cells, which might have resulted in the suppression of carcinogenesis. In conclusion, we found that the chemoprevention of liver cancer by silymarin might be due to its strong hypolipidemic activity.

This study says: Numerous studies have shown that silymarin suppresses COX-2 expression…Silymarin can also down-regulate gene products involved in the proliferation of tumor cells (cyclin D1, EGFR, COX-2, TGF-‚, IGF-IR), invasion (MMP-9), angiogenesis (VEGF) and metastasis (adhesion molecules).

This study says: Recent studies have reported that silymarin and its constituents including silibinin inhibit prostate-specific antigen (PSA) levels regulated by both serum and androgen, causing strong inhibition of human prostate carcinoma LNCaP cell growth… Preclinical results have also shown that silymarin and silibinin cause synergistic effects on cancer cell growth inhibition and apoptotic death by various chemotherapeutic agents, suggesting that these agents should be evaluated in more clinical trials along with other chemotherapeutic agents. In this regard, clinical studies have shown that silymarin treatment in combination with chemotherapeutic agents reduces the toxicity associated with chemotherapy. Silymarin treatment has also shown favorable results in clinical trials in prostate cancer patients and has been suggested as an integral part of a nutraceutical program tailored for cancer management.

Sodium Butyrate
This study says Sodium Butyrate inhibits growth and metastasis in colorectal cancer cells.

Sodium butyrate (NaB) is a short-chain fatty acid which is produced by bacterial fermentation of nondigestible dietary fiber and has been reported to exert anti-tumor effects in many tumors including colorectal cancer (CRC).

Sodium Butyrate and Artemisinin
This study says: The oral intake of artemisinin and its analogs and butyric acid is safe. The artemisinin-butyrate combination may work well, particularly for colon cancer where butyrate concentrations can be raised by simple oral probiotic intake of butyric acidproducing Lactobacilli.

See Artemisinin

Surgery and Immune System

Natural killer (NK) cells are part of a healthy immune system, which is critical to overcoming cancer. They can detect and kill many types of cancer cells but numerous studies tell us that surgery reduces their numbers dramatically.

For example, this study looked at 43 patients with operable breast cancer before and after surgery and found that NK cell activity decreased by over 50 per cent on the first day after surgery and did not return to preoperative levels by day 7.

This study says NK cells play an important role in preventing metastasis.

PSK enhances NK activity
Studies have shown that the natural supplement PSK can enhance NK cell activity. For example, this study analyzed the efficacy of Krestin (PSK) in 225 patients with non-small cell lung cancer (NSCLC). The 5-year survival rates of patients with stages I-II and stage III disease were 39% and 26%, respectively, while the non-administered responder group were only 17% and 8%.
See PSK page

IP6 (inositol hexaphosphate) enhances NK activity
See IP6 page

AHCC (active hexose correlated compound) enhances NK activity
See AHCC page

Curcumin enhances NK activity
This study says angiogenesis, the formation of new blood vessels from host vasculature, is critical for tumor growth and metastases. Curcumin is a direct inhibitor of angiogenesis. Curcumin affects the overall process of angiogenesis by downregulating VEGF, bFGF, and COX-2; inhibiting cell motility, cellular adhesion molecules, endothelial cell migration, invasion, and extracellular proteolysis. It also has antiproliferative and proapoptotic effects on tumor cells. See Curcumin page

Mistletoe enhances NK activity
In this study 62 colorectal cancer patients undergoing open tumour surgery were randomly assigned to either mistletoe infusion or no additional therapy.

NK cell activity differed significantly between the therapy groups 24 h after surgery. NK cell activity of patients treated with mistletoe extract only decreased by 7.9% 24 hours after surgery while control patients saw a 44.4% decrease after 24 hours.

According to these study results, perioperative infusion of mistletoe extracts offers an effective and safe protection against surgery-induced suppression of NK cell activity in colorectal cancer patients.
See Mistletoe page

Aged Garlic Extract (AGE) enhances NK activity
This study says: In this series of in vitro and in vivo studies, we showed that both AGE and PSK could stimulate cell mediated immunity, i.e. activate NK cells and cytotoxic T cells, and subsequently suppress tumor cell growth. PSK, which is prescribed for cancer patients in Japan, is used to enhance the survival of gastric and colon cancer patients and the disease-free period of small cell lung cancer patients when used in combination with chemotherapy agents. The anti-cancer mechanism(s) of PSK appears to be modulation of host immune responsiveness, such as restoration of depressed late phase reaction, enhancement of natural killer cell activity and macrophage functions, augmentation of cytotoxic cell induction, and antagonistic action against humoral immunosuppresive factors produced by a cancer patient

This study says:
The study’s subjects were patients with inoperable colorectal, liver, or pancreatic cancer.In a randomized double-blind trial, AGE was administered to one group and a placebo was administered to another for 6 mo… consisted of 42 patients with liver cancer, 7 patients with pancreatic cancer, and 1 patient with colon cancer…both the number of NK cells and the NK cell activity increased significantly in the AGE group. No adverse effect was observed in either group.

Lactoferrin enhances NK activity
This study says: We report that lactoferrin has a significant effect on natural killer (NK) cell cytotoxicity against haematopoietic and breast epithelial cell lines. Furthermore, we have demonstrated that the increase in NK cell cytotoxicity induced by lactoferrin is only observed at low concentrations of lactoferrin; at high concentrations, lactoferrin decreased NK cell activity.

We have also demonstrated that lactoferrin inhibits epithelial cell proliferation by blocking the cell cycle progression.

This study says: In vitro treatment with Naturin, a new Chinese medical herb, significantly restored lymphocyte proliferation and NK cell activity that were suppressed in cancer patients (Shen et al., 1996). In vivo, Naturin was reported to have significantly improved symptoms of cancer patients including leukemia and lung cancers (Mori et al., 1988).

Cancer Vaccines
Cancer vaccines are produced from a person’s own cancer cells removed during surgery. They are a form of immunotherapy that can help educate the immune system about what cancer cells (including metastatic cancer cells). “look like” so that it can recognize and eliminate them.

This study involved 335 patients with malignant tumors of digestive tract who were treated with autologous [patient’s own] tumor cell vaccine and NDV [Newcastle disease virus] vaccine. After NDV* vaccine immunotherapy, the number of NK cell increased and immune function improved. The study concluded: The autologous tumor cell vaccine and NDV vaccine can prolong the patients’ life.

This study says: In this chapter, we have summarized a number of clinical trials performed in various cancers with focus on the clinical outcome of vaccination therapy. We have also attempted to draw objective inferences from the published data that may influence the clinical effectiveness of vaccination approaches against cancer. Collectively the data indicate that vaccine therapy is safe, and no significant autoimmune reactions are observed even on long term follow-up. The design of clinical trials have not yet been optimized, but meaningful clinical effects have been seen in B-cell malignancies, lung, prostate, colorectal cancer, and melanoma.

This study review found: The most encouraging results were noted in randomised controlled phase II/III trials including over 1300 colorectal carcinoma patients with minimal residual disease. A statistically significantly improved disease-free or overall survival was shown either in all vaccinated or in sub-groups of patients. Promising results were also reported in pancreatic and hepatocellular carcinoma.

In another large randomised study including 567 stage I–IV colorectal carcinoma patients, autologous tumour cells mixed with NDV as an adjuvant was used for vaccination after surgery and compared to surgery alone. A significant prolongation of overall survival duration was seen in the vaccine group. Patients mounting a DTH response to the vaccine survived significantly longer. Six of the 25 patients (24%) with stage IV disease had complete or partial responses in the vaccine group.

In hepatocellular carcinoma (HCC) a tumour-cell-based vaccine combined with adjuvant cytokines significantly improved overall and disease-free survival compared to resection alone. Recurrences were less frequent in patients mounting a DTH response. In a few other studies, immune responses were associated with regression of metastasis or prolongation of disease-free survival.

Nearly a thousand patients with GI malignancies have been enrolled in nine phase II/III randomised controlled vaccination trials. All trials, with the exception of one, showed a statistically significantly improved progression-free or overall survival, either in all vaccinated or in sub-groups of patients. Most of these patients, nearly 700, were vaccinated with autologous tumour cells after surgery. A statistically significantly longer disease-free survival for stage II colon cancer patients was demonstrated using BCG as an adjuvant. Furthermore, autologous tumour cell-based vaccines with NDV or cytokine adjuvants showed a statistically significant overall survival benefit for patients with stages I–IV CRC, as well as stages I–III hepatocellular carcinoma.

Timing of Surgery

This study says: An intriguing controversy regarding the surgical treatment of breast cancer patients in the last two decades was initiated following a publication by Hrushesky et al. who reported that the timing of surgery for the resection of breast cancer tumors within the menstrual cycle influences disease recurrence and patient survival rates. Since then, several independent groups have corroborated these surprising findings, suggesting that the optimal time for the resection is the early luteal phase*. This phenomenon was independent of estrogen receptor status and more prominent in node-positive women.

[ *The luteal phase: The time between ovulation and before the start of menstruation]

Get treated in a high-volume centre

This 2017 study Is the Distance Worth It? Patients With Rectal Cancer Traveling to High-Volume Centers Experience Improved Outcomes which included 18,605 patients says:

“…this is the first study to examine the complex relationship among travel burden, volume, and outcomes among patients with rectal cancer. This study found that patients traveling to high volume centers had superior short-term outcomes including increased odds of lymph node yield and neoadjuvant chemoradiation receipt and lower odds of 30- and 90-day mortality. In addition, we found that patients who traveled to a high-volume center had improved 5-year survival compared with those who were resected at a local low-volume center.

Less Invasive Surgery

Surgery causes huge physical stress to the body, suppressing immunity and increasing the risk of metastasis. Studies show that less invasive surgery such as Laparoscopy and Video-assisted Thoracic Surgery (VATS) lobectomy may be a better option.

Laparoscopy
This study compared Laparoscopy (LAC) to open Colectomy (OC) in 219 patients with Colon cancer. It states: In summary, our results show that LAC should be preferred to OC in patients with colon cancer because it reduces perioperative morbidity, shortens hospital stay, and prolongs cancer-related survival. This latter benefit was mainly due to differences in the subset of patients with stage III tumours, in whom LAC was also associated with lower tumour recurrence and longer overall survival.

This follow-up study of the patients over a 95 month period states: The striking finding of our trial was a higher probability of the cancer-related survival in the LAC group and that LAC was independently associated with a reduced risk of tumor relapse and death from a cancer-related cause when compared with the OC. Interestingly, these differences between the LAC and OC groups were only due to the patients with advanced nonmetastatic cancer (stage III). Conclusions: LAC is more effective than OC in the treatment of colon cancer.

Video-assisted Thoracic Surgery (VATS) lobectomy
This study looked at 204 video-assisted thoracic surgery lobectomies. Results… the 5-year survival rate of pathologic stage I lung cancers after video-assisted thoracic surgery was 97.0%, whereas that after open thoracotomy was 78.5% Conclusions. Pulmonary function and prognosis were far better after video-assisted thoracic surgery lobectomy than after open thoracotomy.It is believed that metastases occur most frequently during the perioperative period, when injury and repair are most prominent and stress can elaborate various humoral substances that potentiate the growth of carcinomas. Thus, Lewis proposed that minimally invasive surgical procedures with the small incisions required for VATS could account for improved long-term survival after a VATS lobectomy.

Choice of Surgical Anaesthesia

Many laboratory studies have suggested that tumor metastasis after cancer surgery may be impacted by surgical anaesthesia techniques.

General or Locoregional anaesthesia?
This study says: Anaesthesia technique could differentially affect cancer recurrence in oncologic patients undergoing surgery, due to immunosuppression, stimulation of angiogenesis, and dissemination of residual cancer cells… Thus, NK cell function seems to be better preserved by locoregional anaesthesia; in addition, the possibility of metastatic disease is significantly limited.

Moreover, the combined use of locoregional anaesthesia with general anaesthesia reduces the amount of general anesthetic required, as well as degree of immunosuppression.

Locoregional analgesia provides better pain control, eliminating the need for opioids in the postoperative period and resulting in negative effects on immune function and tumor growth; it also reduces the release of endogenous opioids.

This study review found: Immunosuppression caused by anesthetic agents should not be ignored, as there are potential ways to circumvent it. One such method is the addition of regional anaesthesia and analgesia to general anaesthesia. This approach reduces the amount of general anaesthesia required during surgery, as well as the quantities of postoperative opioid analgesia, which is itself known to be immunosuppressive… . A retrospective study investigating the effects of regional anaesthesia and analgesia in women who underwent surgery for the resection of breast cancer confirmed our prediction with respect to cancer recurrence. In this study the medical records of 129 patients undergoing mastectomy and axillary clearance were examined. Fifty patients had surgery with paravertebral anaesthesia combined with general anaesthesia, and 79 patients had general anaesthesia combined with postoperative morphine analgesia…after a follow-up period of 24 months only 6% of the regional anaesthesia group showed recurrence, whereas 18% of the general anaesthesia and morphine analgesia group showed recurrence. At 36 months, the difference between the groups increased to 6% vs. 23%, respectively.

This study says: A retrospective analysis of 145 consecutive patients undergoing 156 breast cancer operations using paravertebral block and 100 patients undergoing general anaesthesia during a 2-year period was performed. Conclusions: Paravertebral block can be used to perform major operations for breast cancer with minimal complications and a low rate of conversion to general anaesthesia. Paravertebral block markedly improves the quality of recovery after breast cancer surgery and provides the patient with the option of ambulatory discharge.

A review of our early experience revealed that this regional anesthetic technique enables effective anaesthesia for operative procedures of the breast and axilla, reduces postoperative nausea and vomiting, and provides prolonged postoperative sensory block that minimizes narcotic requirements.

Post-surgery Analgesic

Acute and chronic opioid administration is known to have inhibitory effects on natural killer cell activity according to this study.

This study review advises: …physicians should always try to prescribe postoperative analgesia that is minimally immunosuppressive (e.g., avoid chronic systemic administration of morphine), especially following oncological surgeries. The use of pharmacological interventions perioperatively such as the intervention mentioned above employing a βblocker and a COX2 inhibitor should be considered, as they are feasible and can easily be implemented.

Morphine or Tramadol (or CBD)?
Doctors and cancer care teams may prescribe  opioids such as Morphine or Tramadol for patients having increasing or severe pain from their cancer or their treatment. 

The effects of these drugs on your immune system – and consequently your risk of metastasis / recurrence – is an important consideration.

CBD
This study says: …using CBD for chronic pain in patients using opioids has a significant effect on reducing opioid intake, reducing pain and improving QoL [quality of life]. CBD could significantly reduce opioid use and improve chronic pain and sleep quality among patients who are currently using opioids for pain management.

Morphine or Tramadol
This 2019 study found: Of 2588 breast cancer patients, 36.4% had received tramadol. Those who received tramadol had a 0.71-fold decreased risk of recurrence and a 0.56-fold decrease in mortality. Conclusions. After breast cancer surgery, patients who received tramadol had a decreased risk of postoperative recurrence and mortality.

This study concluded: In conclusion, morphine, fentanyl and tramadol showed comparable analgesic activity in postoperative patients. The immunosuppression of morphine, at least partly, through NF-κB pathway, made it unfavorable for postoperative analgesia. Fentanyl had a different effect on the immune response as seen in vitro and in vivo studies. Tramadol demonstrated immune enhancement both in vitro and in vivo. Therefore, tramadol and fentanyl may be preferred to morphine for the treatment of postoperative pain from the immunological point of view.

This study says: This study compared the effects on immune responses of morphine and of the atypical opioid analgesic, tramadol, given for postoperative pain to gynecological cancer patients. Tramadol and morphine showed comparable analgesic activity; however, tramadol, in contrast to morphine, induced an improvement of postoperative immunosuppression and, therefore, may be preferred to morphine for the treatment of postoperative pain.

In this study says: …evidence exists in the literature suggesting that low NK activity during the peri-operative period can be associated with higher incidence of cancer relapse and mortality in humans. This seems to be particularly true for some breast, neck, lung and colorectal cancers for which the presence of low NK activity is predictive of a poor prognosis…On the basis of the data reported in the present study…and considering the immune profile of tramadol in man in the post-operative period (Sacerdote et al., 2000), we hypothesize that the use of tramadol in the treatment of perioperative pain in cancer patients might be particularly beneficial.

Patients requiring morphine for post-surgery pain control may consider asking their doctor about prescribing Tramadol instead to preserve immunity and thereby decrease the chances of metastasis.


See also:
Surgery Side Effects and solutions
Prepare for Surgery
Vital questions to ask your doctor about surgery


Cancer Treatment Options

Updated September 2024

Please share this page to help others

©2012-2024 cancerireland.ie Proudly powered by WordPress